Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B.
Sakura KirinoNobuharu TamakiMasayuki KurosakiShun KanekoKento InadaYuki TanakaShun IshidoKoji YamashitaTsubasa NobusawaHiroaki MatsumotoYuka HayakawaTatsuya KakegawaMayu HiguchiKenta TakauraShohei TanakaChiaki MaeyashikiYutaka YasuiYuka TakahashiKaoru TsuchiyaHiroyuki NakanishiRyuichi OkamotoNamiki IzumiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
ALT <21 IU/L at 1 year after NA initiation has a lower risk of HCC and could be used as a target value for NA treatment.